Clinical and immunomodulatory effects of combination immunotherapy with low-dose interleukin 2 and tumor necrosis factor alpha in patients with advanced non-small cell lung cancer: a phase I trial.

Yang, S C

Clinical and immunomodulatory effects of combination immunotherapy with low-dose interleukin 2 and tumor necrosis factor alpha in patients with advanced non-small cell lung cancer: a phase I trial. [electronic resource] - Cancer research Jul 1991 - 3669-76 p. digital

Publication Type: Clinical Trial; Journal Article; Research Support, U.S. Gov't, P.H.S.

0008-5472


Adolescent
Adult
Aged
Antigens, Surface--analysis
Antineoplastic Combined Chemotherapy Protocols--therapeutic use
Carcinoma, Non-Small-Cell Lung--immunology
Drug Evaluation
Humans
Interleukin-2--administration & dosage
Killer Cells, Lymphokine-Activated--immunology
Killer Cells, Natural--immunology
Lung Neoplasms--immunology
Middle Aged
T-Lymphocytes--immunology
Tumor Necrosis Factor-alpha--administration & dosage